FY2024 EPS Estimates for Danaher Reduced by Zacks Research

Danaher Co. (NYSE:DHR) – Zacks Research dropped their FY2024 earnings per share (EPS) estimates for Danaher in a research report issued to clients and investors on Tuesday, November 12th. Zacks Research analyst R. Department now expects that the conglomerate will post earnings per share of $7.49 for the year, down from their previous estimate of $7.56. The consensus estimate for Danaher’s current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher’s Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 EPS. The firm’s revenue was up 3.1% on a year-over-year basis.

DHR has been the topic of a number of other research reports. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Stifel Nicolaus raised their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Barclays lowered their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, Leerink Partners increased their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Price Performance

NYSE DHR opened at $239.45 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $172.95 billion, a PE ratio of 46.08, a price-to-earnings-growth ratio of 4.40 and a beta of 0.85. Danaher has a 12-month low of $204.15 and a 12-month high of $281.70. The company has a 50 day moving average price of $263.42 and a two-hundred day moving average price of $260.64.

Hedge Funds Weigh In On Danaher

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new position in shares of Danaher in the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter worth $25,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher in the third quarter valued at about $50,000. 79.05% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.10% of the company’s stock.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.